Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect. Herein, we report a 50-year-old woman with A...
Saved in:
Main Authors: | Xianmeng Chen (Author), Daqing Xia (Author), Xuqin Jiang (Author), Lejie Cao (Author), Jay H. Ryu (Author), Xiaowen Hu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023) -
Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
by: Yan Hu, et al.
Published: (2022) -
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
by: Xia Luo, et al.
Published: (2022) -
The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
by: Zhanjing Dai, et al.
Published: (2024) -
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase-positive non‐small cell lung cancer
by: Joy C. Hsu, et al.
Published: (2021)